<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584489</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0793</org_study_id>
    <nct_id>NCT04584489</nct_id>
  </id_info>
  <brief_title>Iron Metabolism in Cystic Fibrosis</brief_title>
  <official_title>Prevalence and Incidence of Iron Deficiency in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron is a biologically essential micronutrient. Iron deficiency alters erythropoiesis and is&#xD;
      considered as a major cause of disability worldwide. Interestingly, iron overload is never&#xD;
      observed in cystic fibrosis contrarily to others chronic respiratory diseases. Moreover, iron&#xD;
      deficiency reported prevalence in CF is very high (up to 60% in retrospective series) and is&#xD;
      correlated to an alteration of respiratory function.&#xD;
&#xD;
      Cystic fibrosis patients should be tested annually for iron deficiency. Serum ferritin is the&#xD;
      best diagnosis tool for iron deficiency (specificity 87% for a threshold &lt; 30 µg/L).&#xD;
      Previously published studies used less performant markers such as serum iron (&lt; 12 µmol/L) or&#xD;
      transferrin saturation (&lt; 12%), which are markedly influenced by the systemic inflammation.&#xD;
      CF patients experiences frequent pulmonary exacerbations leading to systemic inflammation:&#xD;
      iron stores should therefore be assessed at optimal time with no inflammation.&#xD;
&#xD;
      The I-MUCO study aims to determine the exact prevalence of iron deficiency in CF patients. We&#xD;
      aimed to identify risk factors for iron deficiency onset.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prevalence of iron deficiency defined by serum ferritin ≤ 30 µg/L without inflammatory syndrome (C-reactive protein &lt; 5 mg/L).</measure>
    <time_frame>1 year</time_frame>
    <description>from inclusion to first documented up to 1 year</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Iron Metabolism, Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>iron stores assessment.</intervention_name>
    <description>assessment of iron stores by measuring serum ferritin level (mandatory), serum iron and transferrin saturation.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive patients followed at the referral center for cystic fibrosis of Lyon (France).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cystic fibrosis genetically proven.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Systematic annual follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dietary or drugs iron supplements&#xD;
&#xD;
          -  Systemic inflammation or pulmonary exacerbation&#xD;
&#xD;
          -  Lung transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Quitterie REYNAUD, MD</last_name>
    <phone>00334 78 56 91 05</phone>
    <email>mailto:quitterie.reynaud@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Herve LOBBES, MD</last_name>
    <email>mailto:herve.lobbes@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Ressources et de Compétences de la Mucoviscidose adulte de Lyon - Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quitterie REYNAUD, Dr</last_name>
      <email>quitterie.reynaud@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie VIPREY</last_name>
      <email>marie.viprey@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

